. Author manuscript; available in PMC: 2011 Oct 9.

Published in final edited form as: Gastroenterology. 2009 Jun 12;137(3):856–864.e1. doi: 10.1053/j.gastro.2009.06.006

Table 2.

Overall survival and transplant-free survival for treatment groups stratified by coma category at randomization at 21 days of follow-up.

Outcome	Coma Category at Randomization	Treatment Group		Treatment Group by Outcome for each Coma Category	Overall Treatment Group by Outcome	Breslow-Day

		Placebo	NAC	One sided p-value	One sided p-value	One sided p-value	Odds Ratio (NAC/Placebo)

Overall Survival
21 Days	I – II	75%, n=56	79%, n=58	0.292	0.283	0.262	1.28
	I – II	63% – 87%	68% – 91%	0.292			0.53 – 3.07

	III – IV	53%, n=36	48%, n=23	0.645			0.82
	III – IV	35% – 70%	25% – 70%	0.645			0.29 – 2.34

	Total	66%, n=92	70%, n=81
	Total	56% – 77%	60% – 81%

Transplant-free Survival
21 Days	I – II	30%, n=56	52%, n=58	0.010	0.043	0.012	2.46
	I – II	17% – 43%	38% – 65%	0.010			1.14 – 5.30

	III – IV	22%, n=36	9%, n=23	0.912			0.33
	III – IV	7% – 37%	0% – 22%	0.912			0.06 – 1.74

	Total	27%, n=92	40% n=81
	Total	18% – 37%	28% – 51%